dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Poveda, Andres |
dc.contributor.author | Oaknin Benzaquen, Ana Mazaltob |
dc.contributor.author | Romero, Ignacio |
dc.contributor.author | Guerrero‑Zotano, Angel |
dc.contributor.author | Fariñas Madrid, Lorena |
dc.contributor.author | Rodriguez‑Freixinos, Victor |
dc.date.accessioned | 2021-05-21T10:35:58Z |
dc.date.available | 2021-05-21T10:35:58Z |
dc.date.issued | 2021-02-24 |
dc.identifier.citation | Poveda A, Oaknin A, Romero I, Guerrero-Zotano A, Fariñas-Madrid L, Rodriguez-Freixinos V, et al. A phase I dose-finding, pharmacokinetics and genotyping study of olaparib and lurbinectedin in patients with advanced solid tumors. Sci Rep. 2021 Dec 24;11:4433. |
dc.identifier.issn | 2045-2322 |
dc.identifier.uri | https://hdl.handle.net/11351/5965 |
dc.description | Càncer; Biologia molecular; Oncologia |
dc.description.sponsorship | This trial was sponsored by AstraZeneca and PharmaMar, including supply of study drugs. |
dc.language.iso | eng |
dc.publisher | Nature Research |
dc.relation.ispartofseries | Scientific Reports;11 |
dc.rights | Attribution 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ |
dc.source | Scientia |
dc.subject | Medicaments antineoplàstics |
dc.subject | Càncer |
dc.subject | Medicaments - Eficàcia |
dc.subject.mesh | Dose-Response Relationship, Drug |
dc.subject.mesh | Neoplasms |
dc.subject.mesh | Drug Therapy, Combination |
dc.title | A phase I dose-finding, pharmacokinetics and genotyping study of olaparib and lurbinectedin in patients with advanced solid tumors |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.1038/s41598-021-82671-w |
dc.subject.decs | relación dosis-respuesta de medicamentos |
dc.subject.decs | neoplasias |
dc.subject.decs | farmacoterapia combinada |
dc.relation.publishversion | https://doi.org/10.1038/s41598-021-82671-w |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Poveda A] Oncogynecologic Department, Initia Oncology, Hospital Quironsalud Valencia, Avda Blasco Ibañez, 14, 46 010 Valencia, Spain. [Oaknin A, Fariñas-Madrid L] Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Romero I, Guerrero-Zotano A] Department of Medical Oncology, Fundación Instituto Valenciano de Oncología (IVO), Valencia, Spain. [Rodriguez-Freixinos V] Department of Medical Oncology and Hematology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Canada |
dc.identifier.pmid | 33627685 |
dc.identifier.wos | 000626806200025 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |